Xyrem Settlement Gets Green Light

Law360, New York (July 13, 2007, 12:00 AM EDT) -- A federal judge on Friday approved Jazz Pharmaceuticals Inc.'s $20 million settlement with the federal government over an investigation into the promotion of Xyrem, a narcolepsy treatment containing oft-abused GHB, by Orphan Medical Inc., now a subsidiary of Jazz.

GHB, the popular name for gamma-hydroxybutyrate, is a powerful and almost immediate central nervous system depressant that is often illegally used for recreation. The Health and Human Services Department has classified it as a date rape drug.

Jazz' settlement figure, approved by Judge Eric Vitaliano of the...
To view the full article, register now.